Windtree Therapeutics (NSDQ:WINT) said today that it implemented a 1-for-20 reverse stock split of its issued and outstanding common stock.
The reverse split was approved in November by the holder of the majority of the company’s shares without a meeting of shareholders, according to the Warrington, Penn.-based company.
Get the full story at our sister site, Drug Delivery Business News.
The post Windtree Therapeutics implements 1-for-20 reverse split appeared first on MassDevice.